Neue Studien: Psoriasis im JDDGhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/page/3/?d=1Neue Studien: Psoriasis im JDDGdeUnerwünschte Wirkungen von Januskinase‐Inhibitoren mit Relevanz für den dermatologischen Klinik‐ und Praxisalltaghttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/unerw%C3%BCnschte-wirkungen-von-januskinase%E2%80%90inhibitoren-mit-relevanz-f%C3%BCr-den-dermatologischen-klinik%E2%80%90-und-praxisalltag-r256/No abstract supplied.

Weiterlesen

]]>256Fri, 10 Oct 2025 06:15:28 +0000Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/adverse-effects-of-janus-kinase-inhibitors-with-relevance-for-daily-practice-in-dermatology-r255/Weiterlesen

]]>255Fri, 10 Oct 2025 06:15:28 +0000Successful treatment of palmoplantar pustulosis with topical ruxolitinib.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/successful-treatment-of-palmoplantar-pustulosis-with-topical-ruxolitinib-r244/No abstract supplied.

Weiterlesen

]]>244Thu, 04 Sep 2025 18:54:25 +0000Impfen in der Dermatologie 2025: Update mit Berücksichtigung aktueller Empfehlungen der Ständigen Impfkommissionhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/impfen-in-der-dermatologie-2025-update-mit-ber%C3%BCcksichtigung-aktueller-empfehlungen-der-st%C3%A4ndigen-impfkommission-r200/No abstract supplied.

Weiterlesen

]]>200Sat, 23 Aug 2025 07:41:29 +0000Vitiligohttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/vitiligo-r199/No abstract supplied.

Weiterlesen

]]>199Sat, 23 Aug 2025 07:41:29 +0000Vitiligohttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/vitiligo-r198/No abstract supplied.

Weiterlesen

]]>198Sat, 23 Aug 2025 07:41:29 +0000Pyoderma gangrenosum and spider bites: a case series.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/pyoderma-gangrenosum-and-spider-bites-a-case-series-r197/No abstract supplied.

Weiterlesen

]]>197Sat, 23 Aug 2025 07:41:29 +0000A phase IIb single-center study to assess the efficacy of apremilast for the treatment of nummular eczema.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/a-phase-iib-single-center-study-to-assess-the-efficacy-of-apremilast-for-the-treatment-of-nummular-eczema-r196/BackgroundThe pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase-4.

Patients and methods

A phase IIb randomized, double-blind, placebo-controlled study evaluating the effects of apremilast or placebo in patients with NE. Patients received apremilast (30 mg BID) or placebo until week 16 followed by an open label phase in which all patients were treated with apremilast until week 32. The primary endpoint was the number of patients achieving an improvement in Physician's Global Assessment (PGA) by two or more points or an absolute PGA of 0 or 1 at week 16. Secondary endpoints included changes in skin physiology, life quality, or dermato-pathology.

Results

33 patients were enrolled, of whom 31 were randomized to apremilast (n  =  15) or placebo (n  =  16). 1/15 (6.7%) patients in the apremilast group and 4/16 (25.0%) in the placebo group reached the primary endpoint (p  =  0.369). There was no difference between placebo and apremilast with regard to all secondary endpoints at week 16 and week 32. The safety profile was in accordance with the known safety profile of apremilast.

Conclusion

Phosphodiesterase-4 inhibition by apremilast showed no beneficial effects for the treatment of NE.

Weiterlesen

]]>196Sat, 23 Aug 2025 07:41:29 +0000Pyoderma gangrenosum und Spinnenbisse: eine Fallseriehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/pyoderma-gangrenosum-und-spinnenbisse-eine-fallserie-r195/No abstract supplied.

Weiterlesen

]]>195Sat, 23 Aug 2025 07:41:29 +0000Monozentrische Phase‐IIb‐Studie zur Wirksamkeit von Apremilast beim nummulärem Ekzemhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/monozentrische-phase%E2%80%90iib%E2%80%90studie-zur-wirksamkeit-von-apremilast-beim-nummul%C3%A4rem-ekzem-r194/No abstract supplied.

Weiterlesen

]]>194Sat, 23 Aug 2025 07:41:29 +0000Psoriasis treated with dithranol: a pilot study on in vivo reflectance confocal microscopy.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/psoriasis-treated-with-dithranol-a-pilot-study-on-in-vivo-reflectance-confocal-microscopy-r193/BackgroundThere are only limited histomorphological data on the response of psoriatic skin lesions to topical dithranol. In vivo reflectance confocal microscopy (RCM) in psoriatic skin is highly correlated with histopathological findings and allows non-invasive monitoring of treatment effects on a cellular level.

Patients and methods

Prospective, single-center pilot study at a university-based clinic of dermatology between January 1st and August 30th, 2016. Psoriatic lesions of 20 patients receiving dithranol treatment were assessed by RCM at baseline, day 4 and 8 of treatment.

Results

RCM measurements of psoriatic lesions receiving dithranol treatment revealed epidermal histomorphological changes with a strong median reduction of baseline hyperkeratosis by 45.0% (p < 0.001), acanthosis by 38.2% (p < 0.001), and epidermal thickness by 66.5% (p < 0.001) from baseline until day 8. Moreover, semiquantitative measurements of parakeratosis also showed a significant reduction until day 8 (p < 0.001). Correspondingly, RCM revealed dermal histomorphological changes with a decrease in diameter of dermal papillae by 32.1% (p < 0.001), decrease in diameter of papillary vessels by 16.9% (p = 0.002) and a strong semiquantitative reduction of the inflammatory infiltrate (p < 0.001).

Conclusions

Results from our pilot study indicate that topical dithranol treatment of psoriatic lesions may induce a rapid and marked reduction of pathologic epidermal and dermal RCM features.

Weiterlesen

]]>193Sat, 23 Aug 2025 07:41:29 +0000Routineversorgung von Prurigo nodularis in Deutschland: eine retrospektive Analyse der Krankenakten (ADVANCE PN)https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/routineversorgung-von-prurigo-nodularis-in-deutschland-eine-retrospektive-analyse-der-krankenakten-advance-pn-r162/No abstract supplied.

Weiterlesen

]]>162Thu, 31 Jul 2025 12:43:38 +0000Evaluation of routine care of prurigo nodularis in Germany: retrospective chart review study (ADVANCE PN).https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evaluation-of-routine-care-of-prurigo-nodularis-in-germany-retrospective-chart-review-study-advance-pn-r161/Background and objectivesKnowledge on patient care gaps of prurigo nodularis (PN) is limited. This retrospective chart review (ADVANCE PN) investigated unmet medical needs and gaps in diagnostics, treatment, and management of patients with PN in routine care in Germany.

Patients and methods

Medical records for adults newly diagnosed with PN between January 2012 and December 2022 from dermatologic clinics and office-based dermatologists were analyzed. Baseline demographics, treatment patterns, diagnostics, symptoms, patient-reported outcomes (PROs), and disease-specific scores are reported.

Results

Records of 363 patients from 42 sites were analyzed. Median age (range) was 67 (19-95) years; most patients were female (61.7%), Caucasian (73.4%), and retired (57.3%). Overall, 209 (62.2%) patients had comorbidities (most common: hypertension [28.3%]). Clinically, most patients had nodules (81.1%) or papules (66.7%). PROs, disease-specific scores, and laboratory assessments were performed for 32 (8.8%), 12 (3.3%), and 71 (19.7%) patients, respectively. Topical corticosteroids (TCS) were the most common overall (90.9%) and first-line therapy (84.9%); for second-line therapy, 'no further treatment' was most commonly documented (58.6%).

Conclusions

The findings of ADVANCE PN indicate a high unmet need in the current state of medical care, evidenced by shortcomings in PRO assessment, PN documentation, and adherence to guidelines on PN.

Weiterlesen

]]>161Thu, 31 Jul 2025 12:43:38 +0000Erkennen – Der klinische Blick auf die kutane Tuberkulosehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/erkennen-der-klinische-blick-auf-die-kutane-tuberkulose-r160/No abstract supplied.

Weiterlesen

]]>160Thu, 31 Jul 2025 12:43:38 +0000Recognising cutaneous tuberculosis.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/recognising-cutaneous-tuberculosis-r159/Weiterlesen

]]>159Thu, 31 Jul 2025 12:43:38 +0000Glutenbedingte Hauterkrankungen: Klinik, Diagnostik und Therapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/glutenbedingte-hauterkrankungen-klinik-diagnostik-und-therapie-r158/No abstract supplied.

Weiterlesen

]]>158Thu, 31 Jul 2025 12:43:38 +0000Gluten-related skin disorders: clinical presentation, diagnostic and treatments.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/gluten-related-skin-disorders-clinical-presentation-diagnostic-and-treatments-r157/Weiterlesen

]]>157Thu, 31 Jul 2025 12:43:38 +0000A case of successful treatment of nail psoriasis with abrocitinib.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/a-case-of-successful-treatment-of-nail-psoriasis-with-abrocitinib-r156/No abstract supplied.

Weiterlesen

]]>156Thu, 31 Jul 2025 12:43:38 +0000Optimizing biologics for chronic plaque psoriasis: insights on non-medical interruptions of IL-17, IL-12/23, and IL-23 inhibitors.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/optimizing-biologics-for-chronic-plaque-psoriasis-insights-on-non-medical-interruptions-of-il-17-il-1223-and-il-23-inhibitors-r155/Background and objectivesContinuous biologic treatment is recommended for patients with psoriasis; however, treatment interruption in daily practice is inevitable. The impact of treatment interruption is difficult to study in a real-world setting. In Taiwan, biologics are reimbursed by the National Health Insurance for moderate-to-severe psoriasis for a 2-year course, followed by regulatory discontinuation. Thus, our study provides pragmatic data on the impact of the interruption of biologics treatment for non-medical reasons on therapy effectiveness.

Patients and methods

This single-center retrospective cohort study recruited patients who underwent two consecutive 2-year courses of biologics between 2012 to 2021.

Results

A total of 192 treatment courses from 61 patients were analyzed, with secukinumab and ustekinumab being the most frequently administered biologics. Among patients who continued with the same biologic across two consecutive courses, the time to achieve PASI 75 was shorter during the first course compared to the second, while overall maintenance effects remained similar. Switching to a different biologic usually produced superior results in the second course of treatment.

Conclusions

Although the overall effectiveness after interruption and resumption of treatment with secukinumab or ustekinumab was comparable, the time to achieve PASI 75 was longer following an interruption. Continuous, uninterrupted treatment with a given biologic is therefore recommended whenever possible.

Weiterlesen

]]>155Thu, 31 Jul 2025 12:43:38 +0000Secukinumab for erythrodermic psoriasis combined with sepsis: three case reports.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/secukinumab-for-erythrodermic-psoriasis-combined-with-sepsis-three-case-reports-r144/No abstract supplied.

Weiterlesen

]]>144Sat, 12 Jul 2025 18:34:11 +0000Generalized pustular psoriasis in a patient with asthma following dupilumab and tezepelumab therapy.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/generalized-pustular-psoriasis-in-a-patient-with-asthma-following-dupilumab-and-tezepelumab-therapy-r122/No abstract supplied.

Weiterlesen

]]>122Thu, 26 Jun 2025 16:19:30 +0000Verlängerung der Dosierungsintervalle von IL‐17‐ und IL‐23‐Inhibitoren bei erwachsenen Patienten mit Psoriasis: eine Pilotstudie aus der Praxishttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/verl%C3%A4ngerung-der-dosierungsintervalle-von-il%E2%80%9017%E2%80%90-und-il%E2%80%9023%E2%80%90inhibitoren-bei-erwachsenen-patienten-mit-psoriasis-eine-pilotstudie-aus-der-praxis-r85/No abstract supplied.

Weiterlesen

]]>85Sat, 14 Jun 2025 05:52:56 +0000Treatment adjustment in biologic therapies for moderate-to-severe plaque psoriasis: a German retrospective chart review (TABU).https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/treatment-adjustment-in-biologic-therapies-for-moderate-to-severe-plaque-psoriasis-a-german-retrospective-chart-review-tabu-r62/Background and objectivesFlexible biologic therapy dosing regimens in psoriasis management are common, but data from routine care in Germany are scarce. This study evaluated treatment adjustments for biologic therapies commonly prescribed in Germany.

Patients and methods

Charts for up to 100 consecutive patients treated at 29 centers were reviewed. Data were extracted for adults (aged 18-65 years) with moderate-to-severe plaque psoriasis treated with adalimumab, guselkumab, ixekizumab, secukinumab, or ustekinumab for ≥ 36 weeks. The primary endpoint was time to first treatment adjustment. Secondary endpoints included frequency of and reasons for treatment adjustments. Time to treatment adjustment was analyzed using Kaplan-Meier methods.

Results

Among 982 patients, 297 treatment adjustments in 240 (24.4%) patients were identified. The mean (median; interquartile range) time to first treatment adjustment (n = 223) was 8.4 (4.0; 2.0-12.0) months (secukinumab: 14.1 [10.0; 4.0-21.0], adalimumab: 11.0 [7.0; 3.0-14.5], ustekinumab: 11.0 [6.0; 2.0-16.0], ixekizumab: 5.8 [3.0; 2.0-8.5], guselkumab: 5.1 [3.0; 2.0-7.0]). The most frequent adjustment type was starting concomitant treatment(s) (10.4% of patients); insufficient skin effectiveness was the most frequent reason for adjustment.

Conclusions

Biological treatment adjustments are frequent in moderate-to-severe psoriasis; flexible dosing regimens would support optimal management.

Weiterlesen

]]>62Sun, 01 Jun 2025 17:24:13 +0000Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/is-kaposi-sarcoma-a-novel-comorbidity-of-cutaneous-lymphoma-a-systematic-review-of-the-literature-r51/Background and objectivesPatients with cutaneous lymphomas (CL) are at an increased risk of developing secondary malignancies. This study aimed to assess the frequency of association between CL and Kaposi sarcoma (KS) and to identify factors that may promote the co-occurrence of these two diseases.

Patients and methods

On January 25, 2024, we conducted a systematic search of four electronic medical databases to identify all published cases of KS associated with CL. The clinical course and outcomes of these patients were summarized. For critical appraisal, we applied the JBI Checklist for Case Reports. The study was registered in the PROSPERO database (CRD42022313204).

Results

A total of 40 articles reporting on 45 patients were assessed for eligibility. We included 27 cases in the final analysis (26 cutaneous T-cell lymphomas, 1 cutaneous B-cell lymphoma). In 71% of cases, the diagnosis of CL preceded KS. Nearly half (48%) of the patients had erythrodermic mycosis fungoides or Sézary syndrome. KS lesions were predominantly limited to the skin, with complete remission achieved in 53% of cases.

Conclusions

The association between KS and CL is rare, limiting our study due to the small sample size and potential reporting bias. Skin-targeted therapies, a restricted T-cell repertoire, and impaired T-cell responses in erythrodermic CTCL patients may contribute to the development of KS.

Weiterlesen

]]>51Fri, 30 May 2025 15:05:38 +0000Keine orale Beteiligung in einer großen Kohorte von Frauen mit Lichen sclerosus der Vulva – eine multizentrische prospektive Studiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/keine-orale-beteiligung-in-einer-gro%C3%9Fen-kohorte-von-frauen-mit-lichen-sclerosus-der-vulva-eine-multizentrische-prospektive-studie-r50/No abstract supplied.

Weiterlesen

]]>50Fri, 30 May 2025 15:05:38 +0000